AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32951965 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (flap with graft; n=16)
Number of subjects: 48
Study 32951965 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (flap without graft; n=16)
Number of subjects: 48
Study 32951965 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (flapless without graft; n=16)
Number of subjects: 48
Study 32555026 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Aerobic Interval Training (HIIT) in addition to treatment as usual (n = 13)
Number of subjects: 21
Study 32555026 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n = 8)
Number of subjects: 21
Study 32031041 — intervention group
Group type: EXPERIMENTAL
Intervention: Idealised smile images
Number of subjects: 132
Study 32031041 — intervention group
Group type: COMPARATOR
Intervention: Neutral nature images (Control)
Number of subjects: 132
Study 35216854 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario‐Tailored Opioid Messaging Program (STOMP)
Number of subjects: 503
Study 35216854 — intervention group
Group type: COMPARATOR
Intervention: Routine prescription education
Number of subjects: 503
Study 33321461 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 42
Study 33321461 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 35378230 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 158
Study 35378230 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 158
Study 33469648 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral FUS thalamotomy
Number of subjects: 35
Study 32842819 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valve therapy
Number of subjects: 0
Study 32842819 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up evaluation with CT-scan and/or bronchoscopy
Number of subjects: 0
Study 36177850 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting (DS)
Number of subjects: 72
Study 36177850 — intervention group
Group type: COMPARATOR
Intervention: Conventional stenting (CS) with predilatation
Number of subjects: 72
Study 34510634 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographers with varying levels of expertise (3 general practitioners, 3 credentialed veterinary technicians, 3 board‐certified specialists) performing abdominal ultrasound examinations
Number of subjects: 4
Study 34510634 — intervention group
Group type: COMPARATOR
Intervention: General practitioners
Number of subjects: 4
Study 33377702 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral enucleation and resection of the prostate (TUERP)
Number of subjects: 60
Study 33377702 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 60
Study 32726422 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA‐BN‐RSV vaccine (single dose)
Number of subjects: 0
Study 32726422 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA‐BN‐RSV vaccine (12-month booster dose)
Number of subjects: 0
Study 33976335 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphic SSR loci identified from whole-genome sequences of spinach accessions.
Number of subjects: 48
Study 33976335 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of SSR loci.
Number of subjects: 48
Study 33976335 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic diversity analysis using SSR allele score data.
Number of subjects: 48
Study 32641736 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of pre-radiotherapy PLT and NE
Number of subjects: 0
Study 32641736 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of post-radiotherapy PLT and NE
Number of subjects: 0
Study 32641736 — intervention group
Group type: COMPARATOR
Intervention: Both low levels of PLT and NE
Number of subjects: 0
Study 36097401 — intervention group
Group type: EXPERIMENTAL
Intervention: Jacobson's relaxation technique (JRT)
Number of subjects: 312
Study 32317658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 72
Study 32317658 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 72
Study 32317658 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 72
Study 32317658 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 72
Study 36278483 — intervention group
Group type: COMPARATOR
Intervention: DEN-181 (medium dose)
Number of subjects: 17
Study 36278483 — intervention group
Group type: COMPARATOR
Intervention: DEN-181 (high dose)
Number of subjects: 17
Study 36278483 — intervention group
Group type: EXPERIMENTAL
Intervention: DEN-181 (low/medium doses)
Number of subjects: 17
Study 33905738 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication reconciliation via a patient portal
Number of subjects: 499
Study 33905738 — intervention group
Group type: COMPARATOR
Intervention: Medication reconciliation by a pharmacy technician (usual care)
Number of subjects: 499
Study 32505861 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + goserelin (C + G)
Number of subjects: 227
Study 32505861 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (C)
Number of subjects: 227
Study 32505861 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (C±G)
Number of subjects: 227
Study 35245672 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT)
Number of subjects: 45
Study 35245672 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gel
Number of subjects: 45
Study 35245672 — intervention group
Group type: COMPARATOR
Intervention: Steaming protocol
Number of subjects: 45
Study 33632742 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG/GCSF
Number of subjects: 15
Study 33632742 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG/GCSF responders
Number of subjects: 15
Study 33632742 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders
Number of subjects: 15
Study 33632742 — intervention group
Group type: COMPARATOR
Intervention: Placebo recipients
Number of subjects: 15
Study 32321353 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic Developmental Behavioral Intervention (NDBI)
Number of subjects: 67
Study 32321353 — intervention group
Group type: COMPARATOR
Intervention: Community treatment as usual (Control)
Number of subjects: 67
Study 33292787 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including mHealth technology, under-desk pedal machine, and management consultation.
Number of subjects: 0
Study 33292787 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 0
Study 34697951 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal approach (DA) for local corticosteroid injection (LCI)
Number of subjects: 60
Study 34697951 — intervention group
Group type: COMPARATOR
Intervention: Proximal approach (PA) for local corticosteroid injection (LCI)
Number of subjects: 60
Study 33106117 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery, chemotherapy, and molecularly targeted agents (bevacizumab and PARP inhibitors)
Number of subjects: 5200
Study 33106117 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA testing
Number of subjects: 5200
Study 35044844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal orexin A (500 nmol)
Number of subjects: 10
Study 35044844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 35044844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal orexin A
Number of subjects: 10
Study 32894278 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine and placebo (M + P)
Number of subjects: 133
Study 32894278 — intervention group
Group type: EXPERIMENTAL
Intervention: Miltefosine and topical GM‐CSF (M + GM)
Number of subjects: 133
Study 32894278 — intervention group
Group type: COMPARATOR
Intervention: Pentavalent antimony (Sbv)
Number of subjects: 133
Study 32894278 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 133
Study 32894278 — intervention group
Group type: COMPARATOR
Intervention: Sbv
Number of subjects: 133
Study 32894278 — intervention group
Group type: EXPERIMENTAL
Intervention: M + P
Number of subjects: 133
Study 32894278 — intervention group
Group type: EXPERIMENTAL
Intervention: M + GM
Number of subjects: 133
Study 34853404 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral electrode placement with 600 mA amplitude
Number of subjects: 0
Study 34853404 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral electrode placement with 700 mA amplitude
Number of subjects: 0
Study 34853404 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral electrode placement with 800 mA amplitude
Number of subjects: 0
Study 34853404 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hippocampal E-field
Number of subjects: 0
Study 34853404 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal right hippocampal E-field associated with cognitive safety
Number of subjects: 0
Study 34853404 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain ratio of E-field strength per unit of stimulation current
Number of subjects: 0
Study 35843520 — intervention group
Group type: COMPARATOR
Intervention: Tralokinumab monotherapy (ECZTRA 1 + 2)
Number of subjects: 1976
Study 35843520 — intervention group
Group type: COMPARATOR
Intervention: Tralokinumab plus optional TCS (ECZTRA 3)
Number of subjects: 1976
Study 35843520 — intervention group
Group type: COMPARATOR
Intervention: Tralokinumab (both ECZTRA 1 + 2 and ECZTRA 3)
Number of subjects: 1976
Study 35843520 — intervention group
Group type: COMPARATOR
Intervention: Tralokinumab (both ECZTRA 1 + 2)
Number of subjects: 1976
Study 35403380 — intervention group
Group type: EXPERIMENTAL
Intervention: Azvudine and symptomatic treatment (FNC group)
Number of subjects: 20
Study 35403380 — intervention group
Group type: COMPARATOR
Intervention: Standard antiviral and symptomatic treatment (control group)
Number of subjects: 20
Study 35403380 — intervention group
Group type: EXPERIMENTAL
Intervention: FNC group
Number of subjects: 20
Study 35403380 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 36188376 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A‐tDCS) over the left lip region of the primary motor cortex (M1)
Number of subjects: 24
Study 36188376 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (control group)
Number of subjects: 24
Study 32393732 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, lenalidomide and dexamethasone (VRd)
Number of subjects: 460
Study 32393732 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Rd)
Number of subjects: 460
Study 33420509 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave abnormalities (TWA) present
Number of subjects: 8176
Study 35395075 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear aligners (CA)
Number of subjects: 44
Study 35395075 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliances (FA)
Number of subjects: 44
Study 33466462 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein Meal Replacement (HP-MR)
Number of subjects: 43
Study 33466462 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 43
Study 32702878 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level light therapy (LLLT) using a helmet-type device
Number of subjects: 60
Study 32702878 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 60
Study 34313686 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day antibiotic therapy (ciprofloxacin or trimethoprim/sulfamethoxazole)
Number of subjects: 272
Study 34313686 — intervention group
Group type: COMPARATOR
Intervention: 14-day antibiotic therapy (ciprofloxacin or trimethoprim/sulfamethoxazole)
Number of subjects: 272
Study 33157425 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg fast-release melatonin
Number of subjects: 97
Study 33157425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 34793970 — intervention group
Group type: EXPERIMENTAL
Intervention: Office Suppression Test (3-step procedure to grade suppression on a 4-point scale)
Number of subjects: 57
Study 34793970 — intervention group
Group type: EXPERIMENTAL
Intervention: Office Suppression Test (in subgroup of untreated children)
Number of subjects: 57
Study 33138682 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 40
Study 33138682 — intervention group
Group type: COMPARATOR
Intervention: Placebo version (PTSST)
Number of subjects: 40
Study 34431517 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal reappraisal intervention
Number of subjects: 610
Study 34431517 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 610
Study 34487412 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg rifaximin 3 times/d plus 30-45 mL lactulose 3 times/d
Number of subjects: 100
Study 34487412 — intervention group
Group type: COMPARATOR
Intervention: Lactulose alone (control group)
Number of subjects: 100
Study 35697438 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinical management based on NEWS2 scoring plus PCT‐guided risk assessment
Number of subjects: 7676
Study 35697438 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical management based on NEWS2 scoring alone
Number of subjects: 7676
Study 33992852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 1789
Study 32972965 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based newborn care by Shishu Rakshak (SR)
Number of subjects: 19373
Study 32972965 — intervention group
Group type: COMPARATOR
Intervention: Home-based newborn care by Anganwadi Workers (AWW)
Number of subjects: 19373
Study 32972965 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine health services)
Number of subjects: 19373
Study 33567859 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% high-molecular-weight hyaluronic acid (1 mL)
Number of subjects: 56
Study 33567859 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% low-molecular-weight hyaluronate (1 mL)
Number of subjects: 56
Study 32460220 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneous group
Number of subjects: 42
Study 32460220 — intervention group
Group type: COMPARATOR
Intervention: Homogeneous group
Number of subjects: 42
Study 35993588 — intervention group
Group type: EXPERIMENTAL
Intervention: Remin Pro®
Number of subjects: 50
Study 35993588 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Tooth mousse™
Number of subjects: 50
Study 35993588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride gel
Number of subjects: 50
Study 35993588 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 34587974 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-96W
Number of subjects: 229
Study 34587974 — intervention group
Group type: COMPARATOR
Intervention: ART-Def
Number of subjects: 229
Study 32138344 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day oat beta-glucans
Number of subjects: 83
Study 32138344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 33990147 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS) after curative resection of colon cancer
Number of subjects: 50996
Study 35948382 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of prednisolone for 10 days
Number of subjects: 116
Study 35948382 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo treatment
Number of subjects: 116
Study 33938826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ethamsylate and TXA group (n = 42)
Number of subjects: 126
Study 33938826 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA group (n = 42)
Number of subjects: 126
Study 33938826 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 42)
Number of subjects: 126
Study 32537812 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacy care and pharmacist-led counselling program
Number of subjects: 0
Study 32537812 — intervention group
Group type: COMPARATOR
Intervention: Normal care
Number of subjects: 0
Study 35387919 — intervention group
Group type: EXPERIMENTAL
Intervention: Paprika xanthophylls supplementation
Number of subjects: 0
Study 35387919 — intervention group
Group type: COMPARATOR
Intervention: Control group (no paprika xanthophylls)
Number of subjects: 0
Study 33971105 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive group during ischemic phase
Number of subjects: 28
Study 33971105 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropeptide Y hormone in the ischemic phase
Number of subjects: 28
Study 33971105 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal group
Number of subjects: 28
Study 33324394 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150mg
Number of subjects: 57
Study 33324394 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75mg (escalated to 150mg)
Number of subjects: 57
Study 33324394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 34534664 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART Camp intervention
Number of subjects: 204
Study 34534664 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 204
Study 33275842 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking during pregnancy
Number of subjects: 127
Study 35749352 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment cream (inert unscented lotion) administered by a provider
Number of subjects: 187
Study 32611117 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation strategies based on minimization of individual paths or travel times.
Number of subjects: 0
Study 34882581 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant vaccination with GBM6-AD lysate and poly-ICLC
Number of subjects: 17
Study 34882581 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant vaccines (given to all patients)
Number of subjects: 17
Study 34882581 — intervention group
Group type: COMPARATOR
Intervention: Control group (arm 2, no neoadjuvant vaccination)
Number of subjects: 17
Study 32779711 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise
Number of subjects: 69
Study 32779711 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 69
Study 35616047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg methadone (MET)
Number of subjects: 10
Study 35616047 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg/kg dexmedetomidine (D7)
Number of subjects: 10
Study 35616047 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg/kg dexmedetomidine (D10)
Number of subjects: 10
Study 35616047 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg/kg dexmedetomidine and 0.2 mg/kg methadone (DM7)
Number of subjects: 10
Study 35616047 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg/kg dexmedetomidine and 0.2 mg/kg methadone (DM10)
Number of subjects: 10
Study 35616047 — intervention group
Group type: EXPERIMENTAL
Intervention: Atipamezole (RT30)
Number of subjects: 10
Study 35616047 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (MET)
Number of subjects: 10
Study 35616047 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexmedetomidine (7.5 µg/kg)
Number of subjects: 10
Study 32051972 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan (HA) mouthwash
Number of subjects: 33
Study 35954942 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip (IHG) training, 4 unilateral 2-minute contractions at 30% of maximal voluntary contraction, 5 days per week for 8 weeks
Number of subjects: 22
Study 35954942 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (CON)
Number of subjects: 22
Study 33681993 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus A16 (3 different doses)
Number of subjects: 4
Study 33681993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 33983765 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day pregabalin (EXP 1)
Number of subjects: 16
Study 33983765 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg/day pregabalin (EXP 2)
Number of subjects: 16
Study 33983765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 32449528 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 group
Number of subjects: 141
Study 32449528 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study 33860850 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (2 g for 30 days)
Number of subjects: 6
Study 33860850 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 g whey powder for 30 days)
Number of subjects: 6
Study 32672864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuevo Amanecer (NA‐II) stress management program
Number of subjects: 153
Study 34008159 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-Biofeedback (HRV-BF)
Number of subjects: 46
Study 34008159 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 46
Study 34214639 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐schoolers’ Food Courage 2.0 intervention
Number of subjects: 10
Study 33186683 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 22
Study 33678132 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-delivered compensatory memory skills programme (6 weeks via internet videoconferencing)
Number of subjects: 5
Study 33797347 — intervention group
Group type: EXPERIMENTAL
Intervention: Healer-led training for PPE education and training, general HIV prevention education, and three educational outreach visits.
Number of subjects: 122
Study 33797347 — intervention group
Group type: COMPARATOR
Intervention: Clinician-led training for PPE education and training, general HIV prevention education, and three educational outreach visits.
Number of subjects: 122
Study 32428059 — intervention group
Group type: EXPERIMENTAL
Intervention: LED
Number of subjects: 100
Study 32428059 — intervention group
Group type: EXPERIMENTAL
Intervention: LED/HP
Number of subjects: 100
Study 32428059 — intervention group
Group type: EXPERIMENTAL
Intervention: LED/CP
Number of subjects: 100
Study 32428059 — intervention group
Group type: COMPARATOR
Intervention: HP
Number of subjects: 100